{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-021717","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.672471+00:00","generated_at":"2026-05-16T20:51:12.455985+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elite Pharmaceuticals receives FDA approval for generic Requip XL (ropinirole ER) tablets","bullets":["FDA approved ANDA for generic Requip XL (Ropinirole Extended-Release Tablets USP) in 2,4,6,8,12 mg strengths.","Product indicated for Parkinson's disease; will be marketed under Elite Laboratories label.","IQVIA data: U.S. branded & generic sales of $10M for 12 months ending September 2025.","Approval enables Elite to compete in the ropinirole ER tablet market."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-021717","json":"https://secwatch.observer/filing/0001493152-25-021717.json","markdown":"https://secwatch.observer/filing/0001493152-25-021717.md","text":"https://secwatch.observer/filing/0001493152-25-021717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315225021717/0001493152-25-021717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315225021717/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:51:12.455985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}